Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: A systematic review of virologic and biochemical evidence

AIDS Reviews

Volumn 10, Issue 4, 2008, Pages 212-223

  Martínez Cajas, Jorge L ^a   Pant Pai, Nitika ^b   Klein, Marina B ^b   Wainberg, Mark A ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Drug resistance; Genetic diversity; HIV 1; Non B subtypes

Indexed keywords

ABACAVIR; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; BIOCHEMISTRY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PHENOTYPE; REVIEW; SYSTEMATIC REVIEW; VIRUS GENE; VIRUS STRAIN;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENETIC VARIATION; GENOTYPE; HIV-1; MUTATION;

EID: 59549100674     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Buonaguro L, Tornesello M, Buonaguro F. HIV-1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J Virol. 2007;81:10209-19.
2. Rhee S, Kantor R, Katzenstein D, et al. HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. AIDS. 2006;20:643-51.
3. Brennan C, Brites C, Bodelle P, et al. HIV-1 strains identified in Brazilian blood donors: significant prevalence of B/F1 recombinants. AIDS Res Hum Retroviruses. 2007;23:1434-41.
4. Descamps D, Chaix M, Andre P, et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr. 2005;38:545-52.
5. Holguin A, de Mulder M, Yebra G, Lopez M, Soriano V. Increase of non-B subtypes and recombinants among newly diagnosed HIV-1 native Spaniards and immigrants in Spain. Curr HIV Res. 2008;6:327-34.
6. Locateli D, Stoco P, de Queiroz A, et al. Molecular epidemiology of HIV-1 in Santa Catarina State confirms increases of subtype C in Southern Brazil. J Med Virol. 2007;79:1455-63.
7. Njihia J, Rank C, Remis R, et al. High proportion of non-B viral subtypes among persons with HIV-1 in Ontario, 2003-2005. In: CAHR meeting. Toronto, Canada; 2007.
8. Champenois K, Bocket L, Deuffic-Burban S, et al. Expected response to protease inhibitors of HIV-1 non-B subtype viruses according to resistance algorithms. AIDS. 2008;22:1087-9.
9. Desai S, Kyriakides T, Holodniy M, Al-Salman J, Griffith B, Kozal M. Evolution of genotypic resistance algorithms and their impact on the interpretation of clinical trials: an OPTIMA trial substudy. HIV Clin Trials. 2007;8:293-302.
10. Poonpiriya V, Sungkanuparph S, Leechanachai P, et al. A study of seven rule-based algorithms for the interpretation of HIV-1 genotypic resistance data in Thailand. J Virol Methods. 2008;151:79-86.
11. Snoeck J, Kantor R, Shafer RW, et al. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of HIV are subtype dependent. Antimicrob Agents Chemother. 2006;50:694-701.
12. Kinomoto M, Appiah-Opong R, Brandful J, et al. HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors. Clin Infect Dis. 2005;41:243-51.
13. Fleury H, Toni T, Lan N, et al. Susceptibility to antiretroviral drugs of CRF01Æ, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data. AIDS Res Hum Retroviruses. 2006;22:357-66.
14. Vergne L, Stuyver L, Van Houtte M, Butel C, Delaporte E, Peeters M. Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. J Clin Virol. 2006;36:43-9.
15. Weidle P, Downing R, Sozi C, et al. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative-Uganda. AIDS. 2003;17(Suppl 3):S39-48.
16. Abecasis A, Deforche K, Snoeck J, et al. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS. 2005;19:1799-806.
17. Abecasis A, Deforche K, Bacheler L, et al. Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG. Antivir Ther. 2006;11:581-9.
18. Velazquez-Campoy A, Todd M, Vega S, Freire E. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci USA. 2001;98:6062-7.
19. Velazquez-Campoy A, Vega S, Freire E. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes. Biochemistry. 2002;41:8613-9.
20. Gonzalez L, Brindeiro R, Tarin M, et al. In vitro hypersusceptibility of HIV-1 subtype C protease to lopinavir. Antimicrob Agents Chemother. 2003;47:2817-22.
21. Coman R, Robbins A, Fernandez M, et al. The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease. Biochemistry. 2008;47: 731-43.
22. Clemente J, Coman R, Thiaville M, et al. Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir. Biochemistry. 2006; 45:5468-77.
23. Brenner B, Oliveira M, Doualla-Bell F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS. 2006; 20:F9-13.
24. Coutsinos D, Invernizzi C, Xu H, Brenner B, Wainberg M. In vitro molecular characterization of the development of the K65R and M184V mutations in subtype C HIV-1. Antivir Ther. 2007;12(Suppl 1):S127 [abstract 114].
25. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to NNRTIs. AIDS. 2003;17:F1-5.
26. Marconi V, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first HAART regimen in KwaZulu Natal, South Africa. Clin Infect Dis. 2008;46:1589-97.
27. Doualla-Bell F, Avalos A, Brenner B, et al. High prevalence of the K65R mutation in HIV-1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother. 2006;50:4182-5.
28. Hosseinipour M, Oosterhout J, Weigel R, et al. Resistance profile of patients failing first line ART in Malawi when using clinical and immunologic monitoring. Abstract TUAB0105. In: 17th International AIDS Conference. Mexico City; 2008.
29. Miller M, Margot N, McColl D, Cheng AK. K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials. AIDS. 2007;21:265-6.
30. Hertogs K, de Bethune M, Miller V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant HIV-1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother. 1998;42:269-76.
31. Klimkait T. A sensitive replicative system to assess HIV-1 drug resistance. Am Clin Lab. 2002;21:20-4.
32. Petropoulos C, Parkin N, Limoli K, et al. A novel phenotypic drug susceptibility assay for HIV-1. Antimicrob Agents Chemother. 2000;44: 920-8.
33. Race E, Dam E, Obry V, Paulous S, Clavel F. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS. 1999;13: 2061-8.
34. Verheyen J, Litau E, Sing T, et al. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antivir Ther. 2006;11:879-87.
35. Prabu-Jeyabalan M, Nalivaika E, King N, Schiffer C. Structural basis for co-evolution of a HIV-1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J Virol. 2004;78:12446-54.
36. Myint L, Matsuda M, Matsuda Z, et al. Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant HIV-1. Antimicrob Agents Chemother. 2004;48:444-52.
37. Watkins T, Resch W, Irlbeck D, Swanstrom R. Selection of high-level resistance to HIV-1 protease inhibitors. Antimicrob Agents Chemother. 2003;47:759-69.
38. Gatanaga H, Suzuki Y, Tsang H, et al. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J Biol Chem. 2002;277:5952-61.
39. Robinson L, Gale C, Kleim J. Inclusion of full length HIV-1 gag sequences in viral recombinants applied to drug susceptibility phenotyping. J Virol Methods. 2002;104:147-60.
40. Chaix M, Rouet F, Kouakoussui K, et al. Genotypic HIV-1 drug resistance in HAART-treated children in Abidjan, Cote d'Ivoire. Pediatr Infect Dis J. 2005;24:1072-6.
41. Eshleman S, Jones D, Galovich J, et al. Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations. AIDS Res Hum Retroviruses. 2006;22: 289-93.
42. Bessong P. Polymorphisms in HIV-1 subtype C proteases and the potential impact on protease inhibitors. Trop Med Int Health. 2008;13: 144-51.
43. Agwale S, Zeh C, Paxinos E, et al. Genotypic and phenotypic analyses of HIV-1 in antiretroviral drug-naive Nigerian patients. AIDS Res Hum Retroviruses. 2006;22:22-6.
44. Apetrei C, Descamps D, Collin G, et al. HIV-1 subtype F reverse transcriptase sequence and drug susceptibility. J Virol. 1998;72:3534-8.
45. Caride E, Brindeiro R, Hertogs K, et al. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of HIV-I found in Brazilian patients failing HAART. Virology. 2000;275:107-15.
46. Caride E, Hertogs K, Larder B, et al. Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of HIV-1 found in Brazilian patients failing HAART. Virus Genes. 2001;23:193-202.
47. Grossman Z, Paxinos E, Averbuch D, et al. Mutation D30N is not preferentially selected by HIV-1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother. 2004;48:2159-65.
48. Holguin A, Paxinos E, Hertogs K, Womac C, Soriano V. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J Clin Virol. 2004;31:215-20.
49. Holguin A, Sune C, Hamy F, Soriano V, Klimkait T. Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. J Clin Virol. 2006;36: 264-71.
50. Palmer S, Margot N, Gilbert H, Shaw N, Buckheit R, Miller M. Tenofovir, adefovir, and zidovudine susceptibilities of primary HIV-1 isolates with non-B subtypes or nucleoside resistance. AIDS Res Hum Retroviruses. 2001;17:1167-73.
51. Palmer S, Alaeus A, Albert J, Cox S. Drug susceptibility of subtypes A, B, C, D, and E HIV-1 primary isolates. AIDS Res Hum Retroviruses. 1998;14:157-62.
52. Richard N, Juntilla M, Abraha A, et al. High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B HIV-1. AIDS Res Hum Retroviruses. 2004;20:355-64.
53. Shafer R, Chuang T, Hsu P, White C, Katzenstein D. Sequence and drug susceptibility of subtype C protease from HIV-1 seroconverters in Zimbabwe. AIDS Res Hum Retroviruses. 1999;15:65-9.
54. Tanuri A, Vicente A, Otsuki K, et al. Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil. Antimicrob Agents Chemother. 1999;43:253-8.
55. Gonzalez L, Brindeiro R, Aguiar R, et al. Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of HIV-1 with subtype B and C proteases. Antimicrob Agents Chemother. 2004; 48:3552-5.
56. Quan Y, Brenner B, Marlink R, Essex M, Kurimura T, Wainberg M. Drug resistance profiles of recombinant reverse transcriptases from HIV-1 subtypes A/E, B, and C. AIDS Res Hum Retroviruses. 2003;19:743-53.